BI-2852

BI-2852 is a KRAS inhibitor that binds with nanomolar affinity to a pocket, thus far perceived to be “undruggable,” between switch I and II on RAS. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitors because it binds to a different pocket present in both the active and inactive forms of KRAS. In doing so, it blocks all GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in the low micromolar range in KRAS mutant cells.^[1]

Cells are plated in 96 well plates (1500 cells per well) in the corresponding medium containing 10% FCS. The next day, compounds (Stock: 10 mM in 100% DMSO, including BI-2852), serially diluted in medium are added starting at 50 μM with 1:5 dilutions. Cells are incubated at 37 ℃ and 5% CO2 in a humidified atmosphere for 3 days. Quantification of living cells is performed using the cell titer glow reagent according to the manufacturer's recommendation. Luminescence is read in a 2030 VICTOR X5. Data are fitted by iterative calculation using a sigmoidal curve analysis program based on GraphPAD Prism with variable hill slope.